8-K: Sanara MedTech Inc. Reports Strong Q4 and Full Year 2024 Financial Results, Fueled by Surgical Segment Growth

Sanara MedTech Inc. announced a 49% increase in Q4 net revenue and a 33% increase in full-year net revenue for 2024, driven by strong performance in its Sanara Surgical segment.

Summary

• Sanara MedTech Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 net revenue increased by 49% to $26.3 million, compared to $17.7 million in Q4 2023.
• The company reported a net loss of $1.7 million in Q4, compared to a net loss of $0.3 million in the same period last year.
• Adjusted EBITDA for Q4 was $0.9 million, up from $0.4 million in Q4 2023.
• Full-year net revenue increased by 33% to $86.7 million, compared to $65.0 million in 2023.
• The full-year net loss was $9.9 million, compared to a net loss of $4.4 million in the previous year.
• Adjusted EBITDA for the full year was $2.7 million, a significant increase from $0.1 million in 2023.
• The company's Sanara Surgical segment saw strong growth, while the Tissue Health Plus segment experienced increased losses due to ongoing investments.
• Sanara expects to invest between $7.5 to $10.0 million in Tissue Health Plus in the first half of 2025.
• The company is seeking financial partners to invest in the execution of its Tissue Health Plus strategy.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and strategic initiatives, but tempered by increased net losses and ongoing investments in the Tissue Health Plus segment.

Positives

• Significant revenue growth in both Q4 and full year 2024, driven by the Sanara Surgical segment.
• Substantial improvement in Adjusted EBITDA compared to the previous year.
• Strategic partnerships and acquisitions to expand product offerings and market reach.
• Strengthened balance sheet with increased cash and available borrowing capacity.
• Continued investment in R&D and intellectual property portfolio.
• Expansion of the executive leadership team.
• Amendment to the term loan agreement provides increased financial flexibility.

Negatives

• Net losses increased in both Q4 and full year 2024.
• The Tissue Health Plus segment continues to generate losses due to ongoing investments.
• Operating expenses increased significantly, driven by higher SG&A and R&D costs.
• Other expenses increased due to higher interest expense related to the term loan.
• Royalty revenue decreased to zero for both the three and twelve months ended December 31, 2024.

Risks

• Uncertainties associated with the development and regulatory approval of new products.
• The company's ability to build out its executive team and effectively utilize the proceeds of its term loan.
• The extent of product demand and market acceptance.
• The effect of economic conditions, competition, and pricing.
• The ability to consummate and integrate acquisitions.
• The company's Tissue Health Plus segment is not yet profitable and requires significant investment.

Future Outlook

The company remains focused on driving revenue growth and improving profitability in the Sanara Surgical segment, while continuing to invest in the Tissue Health Plus segment. They plan to launch their first pilot program with a wound care provider group during the second quarter of 2025 and are seeking financial partners to invest in the Tissue Health Plus strategy.

Management Comments

• Our team delivered an impressive conclusion to 2024, with net revenue growth in the fourth quarter of 49% year-over-year, fueled primarily by sales of soft tissue products in our Sanara Surgical segment.
• Throughout 2024, our Sanara Surgical commercial team achieved strong execution with respect to our growth strategy, expanding our coverage and penetration of the markets we serve.
• We also made significant progress in developing the technology platform and infrastructure for Tissue Health Plus, our value-based wound care program.
• In parallel, we continued our efforts to evaluate and pursue new partnerships, enhance our intellectual property portfolio and develop our product pipeline, while securing a new credit facility to provide increased financial flexibility as we pursue our long-term strategy.
• Looking ahead, our team remains focused on driving revenue growth and improving profitability in our Sanara Surgical segment, while continuing to invest in our Tissue Health Plus segment.
• In 2025, we remain focused on improving the profitability in our Sanara Surgical segment, while continuing to invest in our Tissue Health Plus segment in preparation for a planned launch of our first pilot program with a wound care provider group during the second quarter.
• Importantly, we are pursuing financial partners to invest in the execution of our Tissue Health Plus strategy.
• We look forward to expanding awareness and adoption of our technologies this year, with the goal of improving patient outcomes, reducing healthcare costs and enhancing the long-term value of our organization.

Industry Context

Sanara MedTech operates in the advanced wound care and surgical tissue repair markets, which are experiencing growth due to an aging population and increasing prevalence of chronic diseases. The company's focus on developing and commercializing transformative technologies aligns with the industry's trend towards innovative solutions that improve clinical outcomes and reduce healthcare costs. The partnership with Biomimetic Innovations Ltd (BMI) and the development of Tissue Health Plus are strategic moves to expand the company's product portfolio and enter the value-based care market.

Comparison to Industry Standards

• Sanara's revenue growth of 33% for the full year 2024 is strong compared to the overall medical device industry, which typically sees growth in the single to low double-digit percentages.
• Companies like Smith & Nephew and Integra LifeSciences, which also operate in the advanced wound care market, have reported revenue growth in a similar range.
• However, Sanara's net losses are a concern, as many established players in the industry are profitable.
• The company's Adjusted EBITDA margin of 3.1% for the full year 2024 is lower than that of larger, more established medical device companies, which typically have EBITDA margins in the 20-30% range.
• The investment in Tissue Health Plus is a strategic move to differentiate Sanara from its competitors and capitalize on the growing trend towards value-based care, similar to programs offered by companies like Medline and Mölnlycke.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through revenue growth and strategic initiatives, but short-term concerns due to increased net losses.
• Employees: Opportunity for professional growth and development as the company expands its operations.
• Customers: Access to innovative medical technologies that improve clinical outcomes and reduce healthcare costs.
• Suppliers: Potential for increased business as the company's sales grow.
• Creditors: Increased financial stability due to improved Adjusted EBITDA and available borrowing capacity.

Next Steps

• Launch the first Tissue Health Plus pilot program in the second quarter of 2025.
• Continue to drive revenue growth and improve profitability in the Sanara Surgical segment.
• Seek financial partners to invest in the Tissue Health Plus strategy.
• Expand awareness and adoption of the company's technologies.
• Pursue new partnerships and enhance the intellectual property portfolio.

Key Dates

Keywords

Sanara MedTech, financial results, net revenue, adjusted EBITDA, surgical, tissue health, wound care, medical technology, biologics, collagen